Sequencio Presents Cancer Vaccine Data at SITC
Two preclinical cancer vaccine studies from Sequencio Therapeutics will be presented at the SITC 41st Annual Meeting in Phoenix.
Updated on Nov. 4, 2026 in Cancer
Sequencio Therapeutics, a subsidiary of CK Life Sciences, will present two abstracts at the Society for Immunotherapy of Cancer's 41st Annual Meeting, held 4-8 November 2026 in Phoenix, Arizona. The studies evaluate a TROP2 circular RNA vaccine combined with checkpoint inhibition and a dual-antigen PD-L1/PRAME vaccine in preclinical models.
Why it matters
The studies address the challenge of helping the immune system recognise cancer cells and overcoming tumour immune evasion. The company says the results support advancing both vaccine candidates toward human clinical trials.
In the 4T1-hTROP2 model, tumour growth inhibition reached 74.7% with the vaccine plus 0.3 mg/kg anti-PD-1, versus 28.9% for anti-PD-1 alone. Results come from preclinical mouse studies, and human efficacy has not been tested.
The players
Sequencio Therapeutics
A subsidiary of CK Life Sciences Int'l., (Holdings) Inc. developing cancer vaccine programmes built on a Prime-Infiltrate-Ignite-Translate translational research framework.
Society for Immunotherapy of Cancer (SITC)
A professional society that holds an annual meeting focused on cancer immunotherapy research and clinical developments.
The details
CKLS118, a TROP2 circRNA-LNP vaccine, combined with anti-PD-1 therapy increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumours. Separately, the CKLS202 PD-L1/PRAME dual-antigen vaccine showed tumour-free mice protected against rechallenge, with tumour-infiltrating CD4+ cells rising from 0.94% to 2.97%.
Timeline
4-8 November 2026: SITC 41st Annual Meeting in Phoenix, Arizona
6 November 2026: Both posters presented at SITC 2026
Big Picture
The studies build on the checkpoint blockade approach pioneered by PD-1 and PD-L1 inhibitors, which remain a foundation of cancer immunotherapy. Sequencio's work tests whether targeted vaccines can strengthen the T-cell response those drugs depend on.
The vaccines are not yet available to patients, and both remain in preclinical development. Any future clinical use would depend on human trial results showing safety and benefit.
The takeaway
Preclinical results in mice do not guarantee success in people, so these findings are an early step rather than a treatment. Readers should watch for human trial announcements before drawing conclusions about clinical benefit.
Further reading
Explore more research on Cancer treatments and immunotherapy advances.
